Skip to content

Study · Randomized controlled trial · n = 56 · 2016

2 results

Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide.

Saag KG, Agnusdei D, Hans D, Kohlmeier LA, Krohn KD, Leib ES, MacLaughlin EJ, Alam J, Simonelli C, Taylor KA, Marcus R

Arthritis & rheumatology (Hoboken, N.J.)1 Sept 2016Cited by 68 (Europe PMC)

PMID27111239 (opens in a new tab)DOI10.1002/art.39726 (opens in a new tab)PepBankPUB-27111239
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In glucocorticoid-induced osteoporosis, teriparatide increased trabecular bone score from baseline at 18 months and by 3.7% at 36 months.

    In plain wordsIn glucocorticoid-induced osteoporosis, teriparatide increased trabecular bone score from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular bone score
    Study

    n = 56

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · subcutaneous · 36 monthsAs given in this study (human).

    Measurements

    TBS change
    3.7%
    36 months

    Source sentences

    Summary
    In teriparatide-treated patients, TBS was significantly increased at 18 months compared to baseline, and by 36 months had increased 3.7% (P < 0.05).
    1 context sentence
    Summary · context
    Dual x-ray absorptiometry (DXA) results for 53 patients receiving ALN and 56 patients receiving teriparatide who had DXA scans with adequate resolution to perform TBS analysis and completed 36 months of therapy were blindly analyzed for TBS at baseline and 3, 6, 12, 18, 24, and 36 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In glucocorticoid-induced osteoporosis, lumbar spine BMD increased 10.3% with teriparatide at 36 months.

    In plain wordsIn glucocorticoid-induced osteoporosis, spine bone density increased from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · subcutaneous · 36 monthsAs given in this study (human).

    Measurements

    Lumbar spine BMD increase
    10.3%
    teriparatide at 36 months

    Source sentences

    Summary
    At 36 months, increases in lumbar spine BMD were 5.5% and 10.3% in patients treated with ALN and teriparatide, respectively.
    1 context sentence
    Summary · context
    Dual x-ray absorptiometry (DXA) results for 53 patients receiving ALN and 56 patients receiving teriparatide who had DXA scans with adequate resolution to perform TBS analysis and completed 36 months of therapy were blindly analyzed for TBS at baseline and 3, 6, 12, 18, 24, and 36 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00051558

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

Eli Lilly and Companyn = 428Nov 2002 to Jan 2008

Osteoporosis

Trial pageClinicalTrials.govUpdated 12 Mar 2009

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.